Asarina Pharma (Buy, TP: SEK44.00) - Increasing awareness of PMDD
We expect awareness of PMDD to increase in Europe in the coming years, driven by the implementation of the International Classification of Diseases 11th Revision (ICD-11). In our initiation of coverage report in April 2019, we stressed that an upside risk to our investment case was a potential implementation of an ICD code for PMDD. As ICD-11 was recently endorsed at the WHO assembly, we have raised our estimated peak market uptake in Europe. We reiterate our BUY and have raised our target price to SEK44 (37)
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.